# Sandip Ganguly

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sandip-ganguly/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,195 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 13 |
| i10-index | 16 |
| Last Known Institution | Tata Medical Center |
| OpenAlex ID | https://openalex.org/A5004964411 |
| ORCID iD | 0000-0001-8407-6763 |
| Works | 108 |

## Researcher papers

- [Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study](https://scholariq.org/papers/amivantamab-plus-chemotherapy-with-and-without-lazertinib-in-egfr-mutant/)
- [Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study](https://scholariq.org/papers/durvalumab-with-or-without-bevacizumab-with-transarterial-chemoembolisation-in/)
- [Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial](https://scholariq.org/papers/canakinumab-versus-placebo-in-combination-with-first-line-pembrolizumab-plus/)
- [Perspective of Oncology Patients During COVID-19 Pandemic: A Prospective Observational Study From India](https://scholariq.org/papers/perspective-of-oncology-patients-during-covid-19-pandemic-a-prospective/)
- [HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysis](https://scholariq.org/papers/hyport-adjuvant-acute-toxicity-and-patient-dosimetry-quality-assurance-results/)
- [Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trial](https://scholariq.org/papers/hypofractionated-radiation-therapy-comparing-a-standard-radiotherapy-schedule/)
- [Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India](https://scholariq.org/papers/real-world-experience-of-treatment-and-outcome-in-alk-rearranged-metastatic/)
- [Tropical pyomyositis with agammaglobulinaemia.](https://scholariq.org/papers/tropical-pyomyositis-with-agammaglobulinaemia/)
- [PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)](https://scholariq.org/papers/pdl1-expression-and-its-correlation-with-outcomes-in-non-metastatic-triple/)
- [Patterns of recurrence in triple negative breast cancer patients (automated IHC) : An Indian Tertiary Care Center data.](https://scholariq.org/papers/patterns-of-recurrence-in-triple-negative-breast-cancer-patients-automated-ihc/)
- [1339P Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience](https://scholariq.org/papers/1339p-real-world-experience-of-dacomitinib-in-megfr-advanced-nsclc-a-single/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Testicular diseases and treatments](https://scholariq.org/topics/testicular-diseases-and-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Tata Medical Center](https://scholariq.org/institutions/tata-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.